{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:19:49Z","timestamp":1776493189108,"version":"3.51.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2017-87349-R"],"award-info":[{"award-number":["SAF2017-87349-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PIE14\/00034"],"award-info":[{"award-number":["PIE14\/00034"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["Grant 20152031"],"award-info":[{"award-number":["Grant 20152031"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["SBO-140028"],"award-info":[{"award-number":["SBO-140028"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00338","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T08:42:23Z","timestamp":1523349743000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Pridopidine Reverses Phencyclidine-Induced Memory Impairment"],"prefix":"10.3389","volume":"9","author":[{"given":"Kristoffer","family":"Sahlholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Valle-Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Fern\u00e1ndez-Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Ciruela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S0968-0896(01)00011-6","article-title":"A multireceptorial binding reinvestigation on an extended class of sigma ligands: N-[omega-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards sigma1 and EBP sites","volume":"9","author":"Berardi","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"B2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.31887\/DCNS.2006.8.1\/acarlsson","article-title":"A dopaminergic deficit hypothesis of schizophrenia: the path to discovery","volume":"8","author":"Carlsson","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ilar.38.1.41","article-title":"Special Report: The 1996 guide for the care and use of laboratory animals","volume":"38","author":"Clark","year":"1997","journal-title":"ILAR J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"de Yebenes","year":"2011","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"95665","DOI":"10.1172\/jci.insight.95665","article-title":"Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice","volume":"2","author":"Garcia-Miralles","year":"2017","journal-title":"JCI Insight"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","article-title":"Pridopidine activates neuroprotective pathways impaired in Huntington Disease","volume":"25","author":"Geva","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/sj.npp.1301047","article-title":"Phencyclidine-Induced Cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors","volume":"32","author":"Hashimoto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease","volume":"28","year":"2013","journal-title":"Mov. Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/(SICI)1097-4547(19980615)52:6<709::AID-JNR10>3.0.CO;2-U","article-title":"Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex","volume":"52","author":"Johnson","year":"1998","journal-title":"J. Neurosci. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","article-title":"The pharmacology of sigma-1 receptors","volume":"124","author":"Maurice","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1124\/jpet.106.102905","article-title":"The dopamine stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo d2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor sid","volume":"318","author":"Natesan","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.pnpbp.2004.05.004","article-title":"The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition","volume":"28","author":"Nilsson","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1126\/science.2660263","article-title":"Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs","volume":"244","author":"Olney","year":"1989","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1021\/jm901689v","article-title":"Synthesis and evaluation of a Set of 4-Phenylpiperidines and 4-Phenylpiperazines as D 2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine (Huntexil, Pridopidine, ACR16)","volume":"53","author":"Pettersson","year":"2010","journal-title":"J. Med. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","article-title":"In vivo pharmacology of the dopaminergic stabilizer pridopidine","volume":"644","author":"Ponten","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.2174\/1381612819666131216114240","article-title":"The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia","volume":"20","author":"Rajagopal","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"B17","first-page":"489","article-title":"Efficacy, safety, and tolerability of pridopidine in Huntington's disease (HD): results from the phase II dose-ranging study, pride-HD [abstract]","volume":"32","author":"Reilmann","year":"2017","journal-title":"Mov. Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.pnpbp.2005.03.003","article-title":"The dopaminergic stabilizers (\u2212)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats","volume":"29","author":"Rung","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","article-title":"The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease","volume":"97","author":"Ryskamp","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/mp.2012.3","article-title":"The dopamine stabilizers ACR16 and (\u2013)-OSU6162 display nanomolar affinities at the \u03c3-1 receptor","volume":"18","author":"Sahlholm","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1007\/s00213-015-3997-8","article-title":"Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses","volume":"232","author":"Sahlholm","year":"2015","journal-title":"Psychopharmacology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pneurobio.2017.03.008","article-title":"Synaptopathic mechanisms of neurodegeneration and dementia: insights from Huntington's disease","volume":"153","author":"Tyebji","year":"2017","journal-title":"Prog. Neurobiology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.neuropsychologia.2010.01.023","article-title":"Implications of animal object memory research for human amnesia","volume":"48","author":"Winters","year":"2010","journal-title":"Neuropsychologia"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T20:03:41Z","timestamp":1660853021000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":24,"alternative-id":["10.3389\/fphar.2018.00338"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00338","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]},"article-number":"338"}}